Search

Author/Creator Loh, Mei Teng

1. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Issue 10366 (26th November 2022)

Authors:
Urva, Shweta; Coskun, Tamer; Loh, Mei Teng; Du, Yu; Thomas, Melissa K; Gurbuz, Sirel; Haupt, Axel; Benson, Charles T; Hernandez-Illas, Martha; D'Alessio, David A; Milicevic, Zvonko
Journal:
Lancet
Issue:
Volume 400:Issue 10366(2022)
Page Start:
1869
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study. Issue 2 (24th October 2021)

Authors:
Kazda, Christof; Leohr, Jennifer; Liu, Rong; Reddy, Shobha; Dellva, Mary Anne; Loh, Mei Teng; Hardy, Thomas; Plum‐Mörschel, Leona
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 24:Issue 2(2022)
Page Start:
196
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study. Issue 2 (27th October 2021)

Authors:
Leohr, Jennifer; Kazda, Christof; Liu, Rong; Reddy, Shobha; Dellva, Mary Anne; Matzopoulos, Mark; Loh, Mei Teng; Hardy, Thomas; Klein, Oliver; Kapitza, Christoph
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 24:Issue 2(2022)
Page Start:
187
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search